Abstract 71P
Background
Despite durable responses achieved with Immune Checkpoint Inhibitors (ICIs), data about optimal duration of treatment, especially in the context of adverse events, remain scarce.
Methods
A systematic literature search was conducted in three electronic databases until July 2024. Studies referring to melanoma patients who ceased ICIs electively (i.e. due to complete response (CR), protocol completion or patient/physician’s wish) or due to treatment-limiting toxicities (TLTs) were selected. Relapse rates (RRs) post cessation, time to PD, rechallenge and disease control rate (DCR) after 2nd course were the main outcomes. Random-effects models were preferred, and subgroup and sensitivity analyses were conducted to investigate possible sources of heterogeneity.
Results
38 and 35 studies were included in qualitative and quantitative synthesis, respectively. From 2542 patients who discontinued treatment with ICIs, 495 experienced progression (n=34, RR 20.9%,95%CI 17.1–24.7%, I285%); higher rates were detected in patients with TLTs compared to elective disc. Mean time to PD was 14.26 months (n=18, mean time 14.26,95%CI 11.54–16.98,I293%) and was numerically longer in patients ceased for CR compared to patients with TLTs. Treatment duration before cessation was not associated with risk and time to relapse, while mucosal melanomas and non-CR as BOR during treatment led to increased risk for relapse and shorter time to PD compared to other histologic subtypes or CR. Rechallenge with ICI resulted in 57.3% DCR and 28.6% pooled CR rates (n=22, CR rate 28.6%, 95%CI 17.1–40.2, I268%). Subgroup analysis (type of ICI) and sensitivity analyses did not alter the results significantly. Table: 71P
n | Relapse Rate (%,95%CI) | n | Time to PD (mean,95% CI) | n | DCR rate (%,95%CI) | |
Overall population | 34 | 20.9 (17.1 – 24.7) | 18 | 14.2 (11.54 – 16.98) | 22 | 57.3 (43.9 – 70.6) |
Elective disc. | 27 | 15.9 (12.4 – 19.4) | 15 | 14.7 (11.77 – 17.82) | - | |
CR | 22 | 13.2 (10.5 – 16.0) | 14 | 15.8 (12.29 – 19.47) | - | |
TLTs | 14 | 25.9 (18.3 – 33.4) | 5 | 13.1 (9.69 – 16.54) | - |
Conclusions
Discontinuation of ICIs in patients without progression is possible. Outcomes to rechallenge with ICIs may differ depending on the reason for discontinuation, but remains a considerable option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Leiter-Stoppke: Financial Interests, Personal, Advisory Board, and speaker's honoraria: Sun Pharma, Regeneron, Sanofi; Financial Interests, Personal, Advisory Board: Pierre Fabre, Novartis, Almirall Hermal; Financial Interests, Institutional, Research Grant: MSD. L. Flatz: Financial Interests, Personal, Full or part-time Employment, Section Head of Dermato-oncology: University Hospital of Tübingen; Financial Interests, Personal, Stocks/Shares, Founder: Hookipa Pharma, Humion AG; Financial Interests, Personal, Ownership Interest, Founder: Abtherix GmbH, Schmelzberg GmbH; Financial Interests, Personal, Royalties, IP owner together with University of Zurich: Hookipa Pharma; Non-Financial Interests, Personal, Advisory Role: Philogen. T.M.S. Amaral: Financial Interests, Personal, Writing Engagement: CeCaVa, Medtrix; Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pierre Fabre, Neracare; Financial Interests, Personal, Advisory Board: Delcath, Philogen; Financial Interests, Institutional, Funding: Novartis, Neracare, Sanofi, Skyline-Dx, Pascoe, MNI - Naturwissenschaftliches und Medizinisches Institut; Financial Interests, Institutional, Research Grant: Novartis, iFIT; Financial Interests, Institutional, Local PI: IO Biotech, MSD, University Hospital, Essen, Roche, BMS, BioNTech, Philogen, Pfizer, Immunocore, HUYA Bioscience, AstraZeneca, Agenus Inc., Regeneron; Financial Interests, Institutional, Coordinating PI: Unicancer; Non-Financial Interests, Personal, Member: Portuguese Society for Medical Oncology, ASCO; Other, Personal, Other, Clinical expert in the area of medical oncology: INFARMED - PT. All other authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract